U.S. Markets close in 4 hrs 57 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
462.56+1.57 (+0.34%)
As of 11:03AM EDT. Market open.
People also watch
  • Now that we are doing well (I am speaking to longs on Regeneron), I guess the immediate questions how much has this great climb upward already been built in or will it continue to climb on the news yesterday about rheumatoid arthritis. I am thinking that it will climb more now because both Dupixent and Salumibab have great potential. Thoughts are welcome as always.
  • sanofi is the player.

    they're in there buying stock almost every day. and e wet time they ask to increase their position management says ok. long term this stock is going much higher, and I don't mean $535.
  • thanks Martin
  • It has a pipeline, obviously excellent discovery labs, why can't REGN become a MRK, PFE or JNJ?
  • Not a great earnings report to say the least but there is so much good news ahead with two potential blockbuster drugs even if Praulent continues to falter. I think it's going down big time today and maybe for awhile before going up in the way we hope and I anticipate over the next four or five months. Any thoughts are welcome.
  • I see a $500 in the next 6-8 months
  • We are having a nice day today lets hope we have good follow through next week with emphasis next Thursday morning earnings and maybe some other news about these lawsuits. Have a great weekend.
  • Overall I think we will see upside for REGN in the short-term. Perhaps a pullback next day or so could occur I suppose but are yall also seeing a further leg higher? Yo you should really check out awesome-STOCKS, they seem on point with their stocks.
  • Nice little spike in the last 15 minuets. Looks like a potential breakout ahead of earnings. Lets hope it holds and everything they say is very positive. Good luck to us all.
  • "Better than feared" Don't know why I click on these articles.
  • Anyone have thoughts about earnings? I'm debating about adding to my already very large position because I think that in two years it will be much higher but can't figure out whether we will some selling after earnings.
  • 400+ Coming with next week's earnings. Pow!
  • Kramer says that Sanofi should just merge with RGEN. I agree just tare up the agreement about ownership restriction and get it done.
  • REGN gets Thumbs Up from ETFCycle.com


    ETF Cycle
  • REGN just got bumped up from 3 (hold) to 2 (buy) from Zacks today. This is a good sign for the next few months.
  • Amgen: If you can't beat em, rob em!
  • Positive REGN reference in Barron's article over the weekend!
  • AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in Q3 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $50.6 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Lawsuit by Amgen against Regeneron regarding patent infringement.